Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase

Figures & data

Figure 1. Active site view of the superimposed hCA II adducts with its main substrates: CO₂ (green, pdb 2VVA) and bicarbonate (pink, pdb 2VVB) ²⁴. The zinc ion is shown as a grey sphere with its three coordinated protein ligands (green/red), His94, 96 and 119. Amino acid residues involved in the binding of the substrates/inhibitors, at the bottom of the active site, are also shown.

Figure 2. Representation of the superimposed X-ray crystallographic data for hCA II adducts with cyanate (cyan, pdb 4E5Q³¹) bromide (magenta, pdb 1RAZ³²) azide (blue, pdb 1RAY³²) O₂ (presumably as superoxide anion or radical anion; red, pdb 5EOI³³) with a tetrahedrally coordinated active site zinc ion (grey sphere). The key active site zinc ligands (His94, 96 and 119) and “gate-keeping” residues (Thr199, Glu106) are also shown.

Figure 3. Representation of the superimposed hCA II adducted to cyanate (cyan, pdb 4E5Q³¹) bicarbonate (pink, pdb 2VVB²⁴) urea (as anion) (white, pdb 1BV3 [39]), and trithiocarbonate (light blue, pdb 3K7K⁴⁰) The zinc ion (grey sphere), its protein ligands (His94, 96 and 119) and gate-keeping residues (Thr199, Glu106) are also shown.

Figure 4. Representation of the binding of A) O₂⁻ to a Zn²⁺/Cu²⁺ hCA II (pdb 5EOI³³) and B) nitrite to Cu²⁺ substituted Cu₂-hCA II (pdb 6PDV⁴³) Distances of the closest atom of the anion to the metal ion are: Zn-O (in the O₂ adduct) of 1.88 Å; Cu-O (nitrite adduct) of 2.14 Å.

Figure 5. Active site view of A) hCA IX catalytic domain adducted to SLC-0111 (magenta)⁷⁴ and B) hCA II adducted to the three tailed inhibitor 4 (in green).⁷¹ H-bonds are represented as black dashed lines. The Zn(II) ion (grey sphere) and some important amino acid residues involved in the binding of inhibitors are shown.

Figure 6. Historical overview on the discovery of the main chemotypes with CA inhibitory activity.

Figure 7. Active site view of hCA II complexed to A) selenol 11 (pdb 6hX5) ⁹⁶, B) ninhydrin 10 (predicted in silico)¹²⁷ and C) catechol derivative 12 (pdb 6YRI) ¹²⁸. H-bonds are represented as black dashed lines. The Zn(II) ion (grey sphere) and residues involved in its coordination and some active site residues near the binding of inhibitors are shown in CPK colours. Water molecules are shown as red spheres.

Figure 8. hCAs as drug targets^{11,14,51–57}. From edoema and glaucoma, to obesity, neuropathic pain, hypoxic cancers, cerebrovascular diseases and oxidative stress, many isoforms are involved in diverse pathologies for which isoform-selective inhibitors showed a relevant potential to be translated to clinical entities.

Chart 1. Structure of the compounds 1–14 discussed in this review.

(a) Domsic JF, Avvaru BS, Kim CU, et al. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J Biol Chem 2008;283:30766–71.

 PubMed Web of Science ®Google Scholar

(b) Sjöblom B, Polentarutti M, Djinovic-Carugo K. Structural study of X-ray induced activation of carbonic anhydrase. Proc Natl Acad Sci USA 2009;106:10609–13.

 PubMed Web of Science ®Google Scholar

West D, Pinard MA, Tu C, et al. Human carbonic anhydrase II-cyanate inhibitor complex: putting the debate to rest. Acta Crystallogr F Struct Biol Commun 2014;70:1324–7.

 PubMed Web of Science ®Google Scholar

Jönsson BM, Håkansson K, Liljas A. The structure of human carbonic anhydrase II in complex with bromide and azide. FEBS Lett 1993;322:186–90.

 PubMed Web of Science ®Google Scholar

Ferraroni M, Gaspari R, Scozzafava A, et al. Dioxygen, an unexpected carbonic anhydrase ligand. J Enzyme Inhib Med Chem 2018;33:999–1005.

 PubMed Web of Science ®Google Scholar

Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct-an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett 2010;20:474–8.

 PubMed Web of Science ®Google Scholar

Andring JT, Kim CU, McKenna R. Structure and mechanism of copper-carbonic anhydrase II: a nitrite reductase. IUCrJ 2020;7:287–93.

 PubMed Web of Science ®Google Scholar

Bonardi A, Nocentini A, Bua S, et al. Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isoform matching and selectivity of action. J Med Chem 2020;63:7422–44.

 PubMed Web of Science ®Google Scholar

Mboge MY, Mahon BP, Lamas N, et al. Structure activity study of carbonic anhydrase IX: selective inhibition with ureido-substituted benzenesulfonamides. Eur J Med Chem 2017;132:184–91.

 PubMed Web of Science ®Google Scholar

Tanini D, Capperucci A, Ferraroni M, et al. Direct and straightforward access to substituted alkyl selenols as novel carbonic anhydrase inhibitors. Eur J Med Chem 2020;185:111811.

 PubMed Web of Science ®Google Scholar

D'Ambrosio K, Carradori S, Cesa S, et al. Catechols: a new class of carbonic anhydrase inhibitors. Chem Commun (Camb) 2020;56:13033–6.

 PubMed Web of Science ®Google Scholar

(a) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.

 PubMed Web of Science ®Google Scholar

(b) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72.

 PubMed Web of Science ®Google Scholar

Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.

 PubMed Web of Science ®Google Scholar

Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020;40:2485–565.

 PubMed Web of Science ®Google Scholar